Using Lopinavir/Ritonavir for High-Grade Anal Neoplasia in HIV-Positive Patients
Official title: A Phase I Study of Intra-anally Administered Lopinavir/Ritonavir in People Living With HIV (PLWH) With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
Run by University of Wisconsin, Madison · NCT05334004 · Data updated 2026-11-12
This study is testing if a medication called lopinavir/ritonavir, given as a suppository, is safe and effective for people with HIV who have a serious condition called high-grade anal neoplasia.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 21 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | December 19, 2023 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | May 15, 2026 |
| Trial ID | NCT05334004 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are HIV-positive individuals aged 18 and older with biopsy-confirmed high-grade anal intraepithelial neoplasia and a CD4 count greater than 200 cells/mm^3.
✕Probably not a fit
Patients with low-grade anal dysplasia, those with a CD4 count below 200 cells/mm^3, or those currently undergoing systemic chemotherapy or radiation therapy for another cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the safety and tolerability of intra-anal administration of lopinavir/ritonavir in patients living with HIV who have high-grade anal intraepithelial neoplasia (HGAIN). The study will utilize a modified 3 + 3 dose escalation design to identify the maximum tolerated dose (MTD) of the drug, with 30 participants expected to be involved over approximately 3 months, followed by long-term follow-up. Participants will receive the medication via suppository with varying dosing schedules, and secondary outcomes will include measuring the effect on HPV clearance and understanding the mechanism of action of the drug.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with high-grade anal neoplasia, potentially improving their health outcomes.
How similar studies have gone: While this approach is novel in the context of using lopinavir/ritonavir for this specific condition, similar studies have explored the use of protease inhibitors in other contexts, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * willing to provide informed consent * greater than or equal to 18 years of age * Diagnosis of biopsy-confirmed HGAIN * willing to comply with all study procedures Exclusion Criteria: * Diagnosis of low-grade anal dysplasia (AIN, low-grade squamous intraepithelial lesion (LSIL)) by HRA. * CD4 count less than 200 cells/mm\^3 at the time of consideration for entry into the study * unable to provide informed consent * Pregnant or breastfeeding female * Currently receiving systemic chemotherapy or radiation therapy for another cancer.
Where it's running
-
UW Digestive Health Center Anoscopy Clinic
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Evie Carchman, MD, FACS — University of Wisconsin, Madison
- Study coordinator: Cancer Connect, MD, FACS
- Email: clinicaltrials@cancer.wisc.edu
- Phone: 800-622-8922
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Topical treatment for high-grade vulvar lesions
This study is testing a new ointment to see if it can help women with high-grade vulvar lesions caused by HPV without needing surgery.
-
AI-enhanced low-dose CT to screen for pancreatic cancer
This project will test whether an AI tool called PANDA can read low-dose CT scans to find early pancreatic cancer in people aged 50 and older.
-
Using curcumin to treat anal high-grade lesions in HIV patients
This study is testing whether curcumin, a natural compound, can safely treat anal high-grade lesions in people with HIV without the side effects of surgery.
-
Topical treatment for anal high-grade lesions in HIV-negative individuals
This study is testing if an ointment called artesunate can help treat anal high-grade lesions in HIV-negative adults better than a placebo.
-
Performance analysis of an HPV test for anal cancer screening
This study is testing a new HPV test on anal samples to see if it can help high-risk people find anal cancer and precancerous conditions more easily.
-
Evaluating the Gardasil-9 HPV vaccine in adults with HIV
This study is testing how well the Gardasil-9 HPV vaccine works for adults with well-controlled HIV to see if their immune response is similar to those without HIV.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.